Resources
IgA Nephropathy Foundation Announces Launch of Medical and Scientific Advisory Board
May 25, 2022 – The IgA Nephropathy Foundation (IGAN Foundation), a nonprofit dedicated to supporting patients with a rare autoimmune kidney disease called IgA Nephropathy, today announced its formation of a Medical and Scientific Advisory Board (Advisory Board). With the members’ diverse medical and scientific backgrounds, the Advisory Board will help inform and enhance the […]
Read MoreIgan Basics
There is a lot of technical language around IgAN and it can seem confusing and overwhelming when receiving a diagnosis for yourself or a loved one. You may have many questions regarding what it is, how it effects your body, how you got it, and the treatment course that may be available to you. The […]
Read MoreNational Kidney Foundation’s and IgA Nephropathy Foundation’s Externally-Led Patient Focused Drug Development (EL-PFDD) Meeting on IgA Nephropathy
The NKF and IGANF conducted an EL-PFDD meeting on IgAN to inform the FDA on the patient perspective on living with this disease. Understanding the patient perspective will help the FDA when it decides whether to approve potential medicines for IgAN. On August 19, 2019, the National Kidney Foundation and the IGA Nephropathy Foundation of […]
Read MoreTen Years Follow-up of STOP-IgAN Trial
Abstract The randomized, controlled STOP-IgAN trial in patients with IgA nephropathy (IgAN) and substantial proteinuria showed no benefit of immunosuppression added on top of supportive care on renal function over three years. As a follow-up we evaluated renal outcomes in patients over a follow-up of up to ten years in terms of serum creatinine, proteinuria, […]
Read MoreProteinuria Reduction as a Surrogate End Point in Trials of IgA Nephropathy
Abstract IgA nephropathy (IgAN) is an important cause of ESKD for which there are no approved therapies. A challenge for evaluating treatments for IgAN is the usual long time course for progression to ESKD. The aim of this Kidney Health Initiative projectwas toidentify surrogate end points that could serve as reliable predictors of a treatment’s […]
Read More2020 1st Quarter Report – UAB Findings in IgA Nephropathy
Diagnosis of IgA nephropathy The diagnostic feature of immunoglobulin A (IgA) nephropathy (IgAN) is the substantial accumulation of IgA in the filtering structures (glomeruli) of the kidneys. When IgAN was first described in 1968, most patients also had another antibody, IgG, in the glomeruli. The diagnosis of IgAN does not however require IgG to be […]
Read More
IgA February
Volume 03 | February 29, 2020 IgA Nephropathy Foundation News KidneyX Update On Thursday, February 6, the IgAN Foundation attended the KidneyX Congressional Briefing. KidneyX is a public-private partnership between the US Department of Health and Human Services and the American Society of Nephrology to accelerate innovation in the prevention, diagnosis, and treatment of kidney diseases. […]
Read More
Pivotal role found for IgG autoantibodies in IgA nephropathy
The most common form of the kidney disease called glomerulonephritis is IgA nephropathy. Now a study published in the Journal of the American Society of Nephrology by researchers at the University of Alabama at Birmingham largely validates the hypothesis that a second immunoglobulin, IgG, is a crucial part of the pathogenic immunodeposits in glomeruli of patients with IgA nephropathy. […]
Read More